Mesothelioma Multimodal Therapy

Quick Summary

Most mesothelioma patients receive multiple forms of treatment. This is multimodal therapy. The benefits include individually tailored treatment plans and longer life span.

Get a FREE Veterans Packet

Multimodal Treatment of Mesothelioma

Multimodal treatment is important for every mesothelioma patient. A well-cited review in the European Respiratory Journal states that “it is clear that multimodal therapy is necessary to improve long-term results.” Mesothelioma specialists around the world agree: patients need multiple treatment modalities to reach long-term survival.

“Treatment modality” simply means “mode,” it’s a technical term used often by doctors to talk about the different modes of mesothelioma treatment.

Treatment modalities for mesothelioma include:

  • Surgery. When this treatment is combined with one or more other modes, patients have the longest survival times. The type of surgery a doctor chooses depends on your mesothelioma type. It may also vary depending on other treatments you receive.
  • Chemotherapy. Always the standard for systemic cancer treatment, chemotherapy is still an important part of Mesothelioma Treatment. In multimodal treatment, chemo may be given as part of a surgical procedure, radiation or both.
  • Radiation. Often used before, during or after surgery. Doctors may also prescribe radiation as part of a multimodal treatment plan for patients who aren’t eligible for surgery.
  • Emerging therapies. As researchers reach the limits of traditional treatment modes, they have looked for novel solutions. Emerging therapies could unlock the cure for mesothelioma. Combining emerging and traditional therapies increases this potential.
Mesothelioma Veterans GuideGet a FREE Veterans Packet

Get information on:

  • Treatment Options
  • Mesothelioma Specialists
  • Veterans Benefits

Get a Free Veterans Packet

The Key Component of Multimodal Therapy

Mesothelioma specialists widely support surgery as the best treatment for long-term survival. After surgery, it’s easier for doctors to maintain and treat the remaining cancer.

Surgeries used in multimodal treatment include:

Several studies have shown that without a surgical multimodal approach, most patients have a survival time of about 12 months. The multimodal approach can double or triple this survival time.

The type of pleural surgery you receive depends on how your tumors have developed. Nowadays most surgeons are learning the lung-sparing approach. This is largely because of a 2008 study that showed little difference in survival benefits between P/D and EPP. The authors stated that “should be tailored to the extent of disease, patient comorbidities, and type of multimodality therapy planned.”

Did you know?

Multimodal surgical treatment are available in the VA. Veterans are eligible for treatment at one of the 2 VA hospitals that specialize in mesothelioma treatment: the LA and Boston VA Hospitals. The mesothelioma specialists at these centers are the best in the country. Those with VA healthcare can use their benefits to help pay for treatment.


Chemotherapy is often the first treatment a mesothelioma patient gets. Most patients receive a combination of drugs known as Alimta and cisplatin. This drug combination extends survival times by about 3 months. This helps create more time to develop a strong multimodal treatment plan. When combined with surgery, chemotherapy is significantly more effective.

Neoadjuvant and Adjuvant Chemotherapy

Surgical candidates often receive chemotherapy before or after surgery. The neoadjuvant method prescribes chemo before surgery. The adjuvant method prescribes it after. The goal of both methods is simply to make surgery more effective.

Did you know?

One study found that patients who had neoadjuvant chemotherapy and EPP had a median survival of 23 months. This is nearly double the median survival of all mesothelioma patients. The study also reported that, at the time of publishing, 2 patients still showed no signs of mesothelioma more than 38 months after treatment.

It’s unclear whether neoadjuvant or adjuvant is more effective. Patients need a specialist to determine the most effective chemotherapy type.

Mesothelioma Veterans GuideGet a FREE Veterans Packet

Get information on:

  • Treatment Options
  • Mesothelioma Specialists
  • Veterans Benefits

Get a Free Veterans Packet

Intraoperative Treatment

Many mesothelioma specialists use chemotherapy during surgery. This allows them to use larger doses without the risk of severe side effects because the drugs are injected into the bloodstream. Intraoperative chemotherapy is possible in pleural and peritoneal mesothelioma.

The late Dr. David Sugarbaker treated 72 patients using intraoperative chemotherapy from 2001 to 2009. He found that patients with the intraoperative chemo had a median survival of 35 months. These patients lived about 1 year longer than the patients who had surgery without intraoperative chemotherapy.

Peritoneal mesothelioma patients receiving intraoperative chemotherapy have even better survival times. A multicenter analysis of HIPEC (heated intraperitoneal chemotherapy) reported a median survival of 53 months. Over half of the patient recorded lived longer than 4 years after their treatment.

Did you know?

Choosing a cancer center that specializes in mesothelioma is the best way to improve your prognosis. A small study by mesothelioma cancer center reported median survival times greater than 8 years in patients who had HIPEC. They accomplished this through surgical experience and patient-tailored treatment.


Radiation is another important mode of treatment for mesothelioma. Radiation is used in both neoadjuvant and adjuvant methods.

Radiation is most commonly used as an adjuvant therapy. The purpose of following surgery with radiation is to prevent tumors from regrowing. A study of adjuvant radiation reported a median survival of 33 months. More than half of the patients who had surgery plus radiation lived even longer.

Though adjuvant radiation is common, the way specialists look at radiation is changing, because of a 2014 study. Mesothelioma specialists reported on a neoadjuvant radiation method that led to an 84% 3-year survival rate, and all patients in that study were in stage 3 or 4 of their disease. To put this in perspective, the average 2-year survival rate is less than 30% for late-stage mesothelioma patients.

Did you know?

The late-stage patients in the neoadjuvant radiation study were part of a trial called SMART. The acronym means “Surgery for Mesothelioma After Radiation Therapy.” Patients receive high doses of radiation shortly before their diseased lung is removed. Doctors are still testing this method, but the outlook for the future is positive.

Radiation plus chemotherapy is also a popular multimodal treatment plan for advanced mesothelioma. These patients are often ineligible for surgery. The addition of radiation to standard chemotherapy can extend survival.

Trimodal Therapy

The research on multimodal therapy is overwhelming in favor of combining different modes of treatment. It’s natural that doctors have been testing the combination of 3 modes rather than just 2. If surgery and chemotherapy are so effective, wouldn’t surgery, chemotherapy and radiation be best? The answer seems to be “yes.”

Back in 1999, doctors were already reporting patients who doubled their survival times with trimodal therapy. The method involved neoadjuvant chemotherapy and surgery followed by radiation therapy. The doctors also reported that carefully selected patients had even longer survival times. Those patients had median survival times of more than 4 years.

The research on trimodal therapy shows the survival benefit to surgical candidates. But it also highlights the importance of seeing a specialist. Mesothelioma specialists are familiar with this research and know which modes of treatment are most likely to help you.

Emerging Therapies

The progress of traditional modes of cancer therapy have progressed slowly in Mesothelioma Treatment. Researchers have struggled to make chemotherapy and radiation more effective, which is why many doctors are turning to newer forms of cancer treatment.

Some emerging treatments used in multimodal therapy include:

  • Immunotherapy. This treatment uses the immune system to fight mesothelioma cells in the body. It is beneficial for patients who aren’t responding to chemotherapy and those who aren’t eligible for surgery. It also causes few side effects. Doctors have used immunotherapy as a maintenance treatment after surgery with notable success.
  • Gene therapy. Gene therapy, like immunotherapy, uses the body’s own mechanisms to fight mesothelioma. Gene therapy targets mesothelioma cells, leaving healthy cells unharmed. This treatment method is in clinical stages.
  • Photodynamic therapy (PDT). This intraoperative treatment has led to survival times of about 3 years in patients with advanced mesothelioma. It involves a special light-activated drug to kill mesothelioma cells, and it’s applied during P/D surgery. It’s unclear for now whether the PDT or P/D was the main reason for success in that study.

Emerging therapies will, in all likelihood, make a major impact on the course of multimodal therapy for mesothelioma.

Mesothelioma Veterans GuideGet a FREE Veterans Packet

Get information on:

  • Treatment Options
  • Mesothelioma Specialists
  • Veterans Benefits

Get a Free Veterans Packet

Getting Multimodal Therapy

Nearly every mesothelioma survivor received multiple modes of treatment. Whether it was intraoperative chemotherapy, neoadjuvant radiation or a combo of chemo and immunotherapy. One thing remains certain, long-term survival is unlikely without multiple forms of treatment.

Key facts about multimodal treatment:

  • It leads to longer life expectancy
  • Specialists may use different multimodal methods
  • It can be aggressive or relaxed

The modes of treatment you receive largely depend on whether you’re eligible for surgery. Your treatment plan, in this case, may vary widely depending on the cancer center you go to.

For example, the Boston VA Hospital has mesothelioma specialists who use trimodality treatment while the LA VA Hospital may recommend surgery followed by immunotherapy. Patients ineligible for surgery commonly just receive chemotherapy and radiation. Talk to our VA-accredited representative to discuss your options and benefits now.

Veterans Support Team
Todd Gersten, MD PhotoReviewed by:Todd Gersten, MD

Double Board-Certified Oncologist and Hematologist

  • Fact-Checked
  • Editor

Todd Gersten, MD is a double board-certified medical oncologist and hematologist specializing in general adult oncology and hematologic disease. He is a physician partner with the Florida Cancer Specialists and practices in Wellington, Florida.

Dr. Todd Gersten is an independently paid medical reviewer.

Christopher Dryfoos PhotoWritten by:

Contributing Author

Christopher Dryfoos is a journalist and member of the American Medical Writers Association (AMWA). As the grandson of the U.S. Navy’s first forensic pathologist, he aims to help veterans with mesothelioma access needed care.

View Sources
  • American Cancer Society. Survival Statistics for Mesothelioma. Accessed on December 29th, 2017. Retrieved from:
  • Cho, John et al. “A Feasibility Study Evaluating Surgery for Mesothelioma After Radiation Therapy: The “SMART” Approach for Resectable Malignant Pleural Mesothelioma.” Journal of Thoracic Oncology. 2014. Accessed on December 29th, 2017. Retrieved from:
  • Elias, Dominique et al. “Malignant Peritoneal Mesothelioma: treatment with maximal cytoreductive surgery plus intraperitoneal chemotherapy.” Gastroentérologie Clinique et Biologique. 2007. Accessed on December 29th, 2017. Retrieved from:
  • Flores, Raja et al. “Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant Pleural Mesothelioma: Results in 663 patients.” The Journal of Thoracic and Cardiovascular Surgery. 2008. Accessed on December 29th, 2017. Retrieved from:
  • Friedberg, Joseph et al. “Extended Pleurectomy-Decortication–Based Treatment for Advanced Stage Epithelial Mesothelioma Yielding a Median Survival of Nearly Three Years.” Annals of Thoracic Surgery. 2017. Accessed on December 29th, 2017. Retrieved from:
  • Minatel, Emilio et al. “Radical pleurectomy/decortication followed by high dose of radiation therapy for malignant Pleural Mesothelioma. Final results with long-term follow-up.” Lung Cancer. 2014. Accessed on December 29th, 2017. Retrieved from:
  • Sugarbaker, David et al. “Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant Pleural Mesothelioma undergoing surgical macroscopic complete resection.” The Journal of Thoracic and Cardiovascular Surgery. 2013. Accessed on December 29th, 2017. Retrieved from:
  • Sugarbaker, David et al. “Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant Pleural Mesothelioma: Results in 183 patients.” Journal of Thoracic and Cardiovascular Surgery. 1999. Accessed on December 29th, 2017. Retrieved from:
  • Van Schil, Paul E. et al. “Multimodal management of malignant Pleural Mesothelioma: where are we today?” European Respiratory Journal. 2014. Accessed on December 29th, 2017. Retrieved from:
  • Weder, Walter et al. “Neoadjuvant Chemotherapy Followed by Extrapleural Pneumonectomy in Malignant Pleural Mesothelioma.” Journal of Clinical Oncology. Accessed on December 29th, 2017. Retrieved from:
  • Yan, Tristan et al. “Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: Multi-Institutional Experience.” Journal of Clinical Oncology.” Accessed on December 29th, 2017. Retrieved from:
  • Back to Top